Skip to Content

Viagra meets its match: Sex pills for the female libido are on their way

Text SizeAAA

Filed under: Company News, Healthcare, Pfizer

More

The pharmaceutical industry has discovered the female libido. German biotech company Boehringer Ingelheim is "putting the finishing touches on a pill designed to reawaken desire by blunting female inhibitions," according to Bloomberg News, which scientists will discuss next week in Lyon, France.

The drug has nothing to do with George Clooney, or getting male spouses to help more around the house. Turns out women's sex drives are centered in the brain. Who knew? (Not most guys, probably.)

Viagra for Women?

The Boehringer pill could do for women what Pfizer's (PFE) Viagra did for men. U.S. sales for pills boosting the female libido could top the $2 billion spent on erectile dysfunction treatments, Bloomberg estimates, because women report more sexual problems than men.

Decreased sexual desire is a serious problem for women. A Boehringer survey of 31,000 U.S. women 18 and over found that one in 10 expressed distress over diminished sex drive.

Is that a medical problem? The answer isn't so clear-cut. A man's erection is a physical response that can be treated with medicine, but a woman's sexual dissatisfaction is a complex psychological issue. (Pfizer abandoned efforts years ago to create a Viagra for women.) And as Boehringer's scientists note, there's no definitive answer of what constitutes a normal sex drive. A lack of sexual desire is often tied to a woman's relationship with her partner.

A Marketing Challenge

Still, Boehringer may be onto something. Pfizer's marketing playbook for Viagra includes always avoiding the word "impotence"; "erectile dysfunction" has a nicer ring to it, no? Similarly, Boehringer avoids "frigidity" and refers to "hypoactive sexual desire disorder," or HSDD, according to Bloomberg.

Media companies are no doubt as excited about the research as Boehringer. The creative juices on Madison Avenue must be flowing. I have visions of Boehringer ads blanketing shows aimed at women -- soap operas, Oprah, Lifetime movies. Somewhere in Hollywood today, there's surely a hack banging out a comic screenplay about a goofy guy who spikes the cocktails of his bored dates.

Unfortunately, Big Pharma hasn't come up with a drug that solves people's personal problems for them. Now, there's a drug that would be a best-seller.

Reader Comments (Page 1 of 8)

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br /> tags.

Interest Rates

5/1 ARM+4.19%APR: +3.81%
30 Yr.
Fixed Mort.
+5.02%APR: +5.16%
$30K
HELOC
+8.00%APR: 0.00%
30 Mo
New Car Loan
+6.79%APR: 0.00%
1 Yr. CD+1.57%APR: +1.58%
DailyFinance Writers
Melly Alazraki Melly Alazraki Financial writer and analyst
James Altucher James Altucher Financial columnist
Jeff Bercovici Jeff Bercovici Media columnist
Jonathan Berr Jonathan Berr Financial writer and media columnist
Mercedes Cardona Mercedes Cardona Retail reporter
Tim Catts Tim Catts Financial writer
Peter Cohan Peter Cohan Author, venture capitalist and financial writer
Carrie Coolidge Carrie Coolidge Financial writer
Lita Epstein Lita Epstein Financial writer
Sam Gustin Sam Gustin Technology Writer
Nikhil Hutheesing Nikhil Hutheesing Tech and investing editor
Joseph Lazzaro Joseph Lazzaro Markets and economics writer
Latif Lewis Michelle Leder Financial Columnist
Latif Lewis Latif Lewis Business news editor and management columnist
Anthony Massucci Anthony Massucci Senior writer and tech columnist
Doug McIntyre Doug McIntyre Business and investing news writer and editor
Michael Mercurio Michael Mercurio Managing Editor
Todd Pruzan Todd Pruzan Features editor
Michael Rainey Michael Rainey Editor and economics writer
Alex Salkever Alex Salkever Senior technology writer
David Schepp David Schepp Business News reporter
Matthew Scott Matthew Scott Investing reporter and editor
Dan Solin Daniel R. Solin Author, investment advisor and retirement expert
Amey Stone Amey Stone Executive editor
Bruce Watson Mark Svenvold Columnist, renewable energy
Russel Turk, M.D. Russell Turk, M.D. Healthcare policy columnist
Bruce Watson Bruce Watson Features Writer
my portfolios

Find out why more people track their portfolios on AOL Money & Finance than anywhere else.

Create a New Portfolio My Portfolios

Daily Finance Partners

More from the Weblogs Network